MedTrace Logo

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

NCT05733286 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2026-01-15

Study results available
· View outcomes & findings →

Summary

This research study will evaluate the effectiveness of postoperative administration of a drug called suvorexant, to improve postoperative sleep and decrease the severity of delirium (serious confusion) in adults 65 years and older undergoing non-cardiac surgery.

Conditions

  • Delirium in Old Age

Interventions

DRUG

Suvorexant 20 mg

Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2

DRUG

Placebo

Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2

Sponsors & Collaborators

Principal Investigators

  • Michael Devinney Jr, MD, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-28
Primary Completion
2025-06-25
Completion
2025-07-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733286 on ClinicalTrials.gov